title: Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial.
abstract: BACKGROUND
  Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients.
  
  
  OBJECTIVE
  To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes.
  
  
  METHODS
  Six primary care units of the Brazilian public health system, Ouro Preto, Brazil.
  
  
  METHODS
  An open, randomised, controlled clinical trial was conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels ≥7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C.
  
  
  RESULTS
  A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (-0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors.
  
  
  CONCLUSIONS
  This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.
authors.affiliation: Post-Graduate Program in Pharmaceutical Sciences, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Brazil.
authors.forename: Aline Oliveira Magalhães
authors.initials: AO
authors.lastname: Mourão
authors.forename: Wandiclécia Rodrigues
authors.initials: WR
authors.lastname: Ferreira
authors.forename: Maria Auxiliadora Parreiras
authors.initials: MA
authors.lastname: Martins
authors.forename: Adriano Max Moreira
authors.initials: AM
authors.lastname: Reis
authors.forename: Maria Ruth Gaede
authors.initials: MR
authors.lastname: Carrillo
authors.forename: Andrea Grabe
authors.initials: AG
authors.lastname: Guimarães
authors.forename: Lisiane Silveira
authors.initials: LS
authors.lastname: Ev
mesh_terms: D000368:Aged; D001938:Brazil; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010593:Pharmaceutical Services
chemical_list: D006442:Glycated Hemoglobin; C517652:hemoglobin A1c protein, human